ADMA Biologics: The Short Report Is The Noise, Not The Signal (NASDAQ:ADMA)

ADMA Biologics (ADMA) is still a Buy after a 40% drop—Asceniv demand and pricing hold strong, DSO risks easing, and 2026–2029 revenue targets rise.

You will be redirected in 10 seconds.

liveinternet liveinternet